The US Food and Drug Administration (FDA) alerted the public late Monday of a post-marketing safety clinical trial for Xeljanz (tofacitinib) that found an increased risk of lung blood clots and death ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results